ClinicalTrials.gg
Not yet recruitingNCT07693907CSM-T-IBSUpdated Jul 15, 2026

A Taiwan-Adapted Self-Management Program for Adults With Irritable Bowel Syndrome

An interventional study of Comprehensive Self-Management Program and Usual Care in Irritable Bowel Syndrome, sponsored by National Defense Medical Center, Taiwan. Not yet recruiting. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by National Defense Medical Center, Taiwan · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Study summary

This pilot randomized controlled trial will evaluate the feasibility, acceptability, and preliminary effects of a Taiwanese version of a comprehensive self-management program for adults with irritable bowel syndrome. Participants will be randomized to the self-management program or usual care. Outcomes will be assessed at baseline, immediately after the intervention, and three months after the intervention.

Read the detailed description

The study will enroll adults with irritable bowel syndrome and randomize participants in a 2:1 ratio to an 8-session comprehensive self-management program or usual care. The program includes irritable bowel syndrome education, symptom monitoring, relaxation practice, cognitive strategies, dietary self-management, sleep-related content, problem solving, and daily-life symptom management. The pilot trial will assess recruitment, retention, intervention adherence, acceptability, satisfaction, and preliminary changes in symptom-related outcomes.

02

Conditions studied

  • Irritable Bowel Syndrome

Keywords

  • irritable bowel syndrome
03

In context

Irritable Bowel Syndrome

1,121 studies on the registry are indexed under Irritable Bowel Syndrome; 212 are open to participants now.

This study's planned enrollment of 54 is below the median of 70 across 900 interventional studies indexed under Irritable Bowel Syndrome.

Browse Irritable Bowel Syndrome studies →

Lead sponsor

National Defense Medical Center, Taiwan is the lead sponsor of 64 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:Adults aged 20 to 70 years

  1. Meets Rome criteria for irritable bowel syndrome
  2. Has a healthcare provider diagnosis of irritable bowel syndrome
  3. Able to read and speak Mandarin
  4. Willing to provide and participate in study procedures

Exclusion Criteria:

  1. Pregnant or breastfeeding
  2. Poorly controlled mental health problems, including history of psychosis, bipolar disorder, drug or alcohol abuse or dependence, or suicide attempt within the past 2 years unless explained by significant loss
  3. Surgery or hospitalization within the past month
  4. Unable to complete study questionnaires or study procedures
  5. Unable to complete study questionnaires or study procedures -
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Comprehensive Self-Management Program

    Participants assigned to this arm will receive an 8-session Taiwan-adapted comprehensive self-management program for irritable bowel syndrome over approximately 8 weeks, in addition to scheduled study assessments. The program includes irritable bowel syndrome education, symptom monitoring, relaxation practice, cognitive strategies, dietary self-management, sleep-related content, problem solving, and daily-life symptom management.

    Behavioral: Comprehensive Self-Management Program

  • Other
    Usual Care

    Participants assigned to this arm will continue to receive usual clinical care and complete scheduled study assessments.

    Other: Usual Care

Interventions

  • BehavioralComprehensive Self-Management Program

    Participants assigned to the intervention group will receive an 8-session comprehensive self-management program over approximately 8 weeks. The program includes irritable bowel syndrome education, symptom monitoring, relaxation practice, cognitive strategies, dietary self-management, sleep-related content, problem solving, and daily-life symptom management.

  • OtherUsual Care

    Participants assigned to the usual care group will continue to receive usual clinical care and complete scheduled study assessments.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Who Complete the 3-Month Follow-Up Assessment

    The proportion of enrolled participants who complete the 3-month post-intervention assessment will be calculated.

    Time frame: From enrollment to 3 months post-intervention

  2. Proportion of Intervention Sessions Completed

    The proportion of assigned intervention sessions completed by participants in the comprehensive self-management program group will be calculated.

    Time frame: From Week 1 to Week 8

  3. Mean Acceptability Score Immediately Post-Intervention

    Acceptability of the study procedures and intervention will be assessed using investigator-developed acceptability items. Higher scores indicate greater acceptability.

    Time frame: Immediately post-intervention

  4. Proportion of Participants With Complete Questionnaire Data

    The proportion of participants with complete questionnaire data at each assessment time point will be calculated.

    Time frame: Baseline, immediately post-intervention, and 3 months post-intervention

Secondary outcomes

  1. Change From Baseline in Irritable Bowel Syndrome Quality of Life Score Immediately Post-Intervention and at 3 Months Post-Intervention

    Irritable bowel syndrome-related quality of life will be assessed using the Irritable Bowel Syndrome Quality of Life questionnaire. Total scores range from 0 to 100, with higher scores indicating better quality of life.

    Time frame: Baseline, immediately post-intervention, and 3 months post-intervention

  2. Change From Baseline in Irritable Bowel Syndrome Symptom Severity Scale Score Immediately Post-Intervention and at 3 Months Post-Intervention

    Irritable bowel syndrome symptom severity will be assessed using the Irritable Bowel Syndrome Symptom Severity Scale. Total scores range from 0 to 500, with higher scores indicating greater symptom severity.

    Time frame: Baseline, immediately post-intervention, and 3 months post-intervention

  3. Change From Baseline in Percentage of Days With Moderate to Very Severe Gastrointestinal Symptoms Immediately Post-Intervention and at 3 Months Post-Intervention

    Daily gastrointestinal symptoms will be assessed using a daily symptom diary over 2 weeks. The score will be calculated as the percentage of days with at least one moderate to very severe gastrointestinal symptom, ranging from 0% to 100%. Higher percentages indicate more frequent moderate to very severe gastrointestinal symptoms.

    Time frame: Baseline, immediately post-intervention, and 3 months post-intervention

  4. Change From Baseline in Patient-Reported Outcomes Measurement Information System Fatigue T-Score Immediately Post-Intervention and at 3 Months Post-Intervention

    Fatigue will be assessed using the Patient-Reported Outcomes Measurement Information System Fatigue scale. Scores are reported as standardized T-scores, with a mean of 50 and a standard deviation of 10 in the reference population. Higher scores indicate greater fatigue.

    Time frame: Baseline, immediately post-intervention, and 3 months post-intervention

  5. Change From Baseline in Patient-Reported Outcomes Measurement Information System Sleep Disturbance T-Score Immediately Post-Intervention and at 3 Months Post-Intervention

    Sleep disturbance will be assessed using the Patient-Reported Outcomes Measurement Information System Sleep Disturbance scale. Scores are reported as standardized T-scores, with a mean of 50 and a standard deviation of 10 in the reference population. Higher scores indicate greater sleep disturbance.

    Time frame: Baseline, immediately post-intervention, and 3 months post-intervention

  6. Change From Baseline in Patient-Reported Outcomes Measurement Information System Anxiety T-Score Immediately Post-Intervention and at 3 Months Post-Intervention

    Anxiety symptoms will be assessed using the Patient-Reported Outcomes Measurement Information System Anxiety scale. Scores are reported as standardized T-scores, with a mean of 50 and a standard deviation of 10 in the reference population. Higher scores indicate greater anxiety symptoms.

    Time frame: Baseline, immediately post-intervention, and 3 months post-intervention

  7. Change From Baseline in Patient-Reported Outcomes Measurement Information System Depression T-Score Immediately Post-Intervention and at 3 Months Post-Intervention

    Depressive symptoms will be assessed using the Patient-Reported Outcomes Measurement Information System Depression scale. Scores are reported as standardized T-scores, with a mean of 50 and a standard deviation of 10 in the reference population. Higher scores indicate greater depressive symptoms.

    Time frame: Baseline, immediately post-intervention, and 3 months post-intervention

  8. Change From Baseline in Visceral Sensitivity Index Score Immediately Post-Intervention and at 3 Months Post-Intervention

    Gastrointestinal symptom-specific anxiety will be assessed using the Visceral Sensitivity Index. Total scores range from 0 to 75, with higher scores indicating greater gastrointestinal symptom-specific anxiety.

    Time frame: Baseline, immediately post-intervention, and 3 months post-intervention

  9. Change From Baseline in Work Productivity and Activity Impairment Percentage Immediately Post-Intervention and at 3 Months Post-Intervention

    Work productivity and activity impairment will be assessed using the Work Productivity and Activity Impairment Questionnaire-Irritable Bowel Syndrome. Scores are reported as percentages from 0% to 100%, with higher percentages indicating greater impairment.

    Time frame: Baseline, immediately post-intervention, and 3 months post-intervention

  10. Proportion of Participants Reporting Use of at Least One Self-Management Strategy at 3 Months Post-Intervention

    Use of self-management strategies will be assessed by asking participants how often they use each strategy. The proportion of participants reporting use of at least one self-management strategy will be calculated.

    Time frame: 3 months post-intervention

  11. Change From Baseline in Gut Microbiome Shannon Diversity Index Immediately Post-Intervention

    Gut microbiome Shannon diversity index will be calculated from stool samples using 16S ribosomal RNA gene sequencing. Higher values indicate greater within-sample microbial diversity.

    Time frame: Baseline and immediately post-intervention

  12. Change From Baseline in Gut Microbiome Richness Immediately Post-Intervention

    Gut microbiome richness will be calculated from stool samples using 16S ribosomal RNA gene sequencing. Higher values indicate a greater number of observed microbial taxa.

    Time frame: Baseline and immediately post-intervention

  13. Change From Baseline in Fecal Calprotectin Concentration Immediately Post-Intervention

    Fecal calprotectin concentration will be measured from stool samples using enzyme-linked immunosorbent assay. Results will be reported in micrograms per gram of stool, with higher values indicating greater intestinal inflammation.

    Time frame: Baseline and immediately post-intervention

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be made available to other researchers. The study involves a small pilot sample and collects symptom-related and psychosocial data from adults with irritable bowel syndrome. Public or external sharing of individual participant data may increase the risk of participant re-identification and is not planned under the current informed consent and ethics approval.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Dec 2027, 17 months later.

Of 308 non-industry interventional studies with no phase under Irritable Bowel Syndrome, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's planned 17 months is below that.

Counting every sponsor, half of 360 studies reached it within 19 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2026
First posted
Jul 9, 2026
StartEst.
Jul 15, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jul 25, 2028
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07693907
Lead sponsor
National Defense Medical Center, Taiwan
Collaborators
Tri-Service General Hospital (TSGH), National Health Research Institutes, Taiwan
Responsible party
Pei-Lin Yang (Associate Professor, National Defense Medical Center, Taiwan) — Principal investigator
First posted
Jul 9, 2026
Start date
Jul 15, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Jul 25, 2028 (estimated)
Last update
Jul 15, 2026

Study contacts

Pei-Lin Yang, PhD
Contact
peilinyang@mail.ndmutsgh.edu.tw
+886-2-8792-3100 ext. 18778
Pei-Lin Yang, PhD
principal investigator · School of Nursing National Defense Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion